12:00 AM
 | 
Oct 26, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AL-335: Phase IIa started

Johnson & Johnson began an open-label Phase IIa trial to evaluate a once-daily oral regimen of Olysio/ Sovriad simeprevir, AL-335 and odalasvir ( ACH-3102) for 4, 6 or 8 weeks in about 60 patients. J&J’s Janssen...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >